Adalimumab
Brand: Humira ®
NICE TA: 373
Indication: Juvenile idiopathic arthritis in children and young people (NICE TA373)
Disease category: Musculoskeletal system
Commissioning responsibility: NHS England
PbR excluded: Yes
Background
Adalimumab is recommended as an option for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is:
- for people 2 years and older whose disease has responded inadequately to 1 or more DMARD.
Adalimumab is recommended as an option for treating enthesitis-related JIA, that is, for people 6 years and older whose disease has responded inadequately to, or who are intolerant of, conventional therapy.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |